Correction to: Review of a new fully liquid, hexavalent vaccine: Hexaxim
Nunes MC, Madhi SA. Expert Opin Biol Ther 2013;13(4):575-93.
Since publication of the article Review of a new fully liquid, hexavalent vaccine: Hexaxim, detailed above, errors in the text have been identified.
The Editor and Authors of the article would like to correct the following:
In the Introduction, Hexavac is attributed to Sanofi Pasteur, Lyon, France. Hexavac was actually a Sanofi Pasteur-MSD joint venture product, not simply Sanofi Pasteur. The hep B antigen in Hexavac came from MSD. This is an important and clear distinction between Hexavac and Hexaxim.
In section 3.1 on page 3, the first of the three dosing schedules for the three-dose primary series was 2, 3, and 4 months of age, not 2, 3, and 6 months as incorrectly stated.
At the end of section 6, the following paragraph should be corrected from:
“The complete development of the new hexavalent vaccine was so far restricted to Latin America and Asia. Because there may be differences in immune responses between ethnic groups, introduction of these vaccines into settings such as Europe and North America will need to be preceded by immunogenicity studies in populations reflective of those.”
To
“The complete development of the new hexavalent vaccine was so far restricted to Latin America, Asia, Turkey and South Africa with studies ongoing in Europe. Because there may be differences in immune responses between ethnic groups, introduction of these vaccines into settings such as Europe and North America will need to be preceded by immunogenicity studies in populations reflective of those.”
In the Introduction, the authors state “This evaluation was supported by results of clinical trials comparing the new hexavalent vaccine to licensed combination vaccines involving ∼ 4,000 infants in Central and South America, South Africa, Turkey and Thailand.” This should state “…more than 4000 infants who received Hexaxim…”
In the introduction, the sentence “These monovalent and combination vaccines have been approved in > 100 countries since 1997 [8].” Should read “Monovalent and combination vaccines are widely licensed and distributed, e.g., Pentaxim was approved since 1997 and is now licensed in over 100 countries [8]”
The authors, editors and publisher sincerely regret any inconvenience this may have caused our readers.